Strikingly, our findings implicate dysregulation of PRAJA1 in the pathogenesis of Alzheimer’s disease, positioning PRAJA1 as a potential therapeutic target for cognitive enhancement in neurodegenerative conditions. Here, PJA1 is linked to early-onset autosomal dominant Alzheimer disease.